Limited Period Offer:Be a PRO for 1 month @Rs49/-Multiple payment options available. Know More
you are here: HomeNewsIndia

Supreme Court questions dual COVID-19 vaccine pricing for Centre, states

The Supreme Court bench did not pass any orders on COVID-19 vaccine pricing, but asked the Centre to examine issue, Bar & Bench reported.

April 30, 2021 / 02:48 PM IST
Supreme Court (Image: Shutterstock)

Supreme Court (Image: Shutterstock)

The Supreme Court (SC) on April 30 questioned the different pricing of COVID-19 vaccines for Centre and state governments.

A three-judge Bench of Justices DY Chandrachud, L Nageswara Rao and Ravindra Bhat was hearing the suo motu case on issues related to COVID-19 management.

The SC bench did not pass any orders in this regard, but asked the Centre to examine issue, Bar & Bench reported.

"AstraZeneca is providing vaccines at far lower price to the US citizens then why should we be paying so much? Manufacturers are charging you Rs 150 but Rs 300 or Rs 400 to States. Why should we as a nation pay this, the price difference becomes 30 to 40,000 crores?" Justice Bhat said, as quoted by Bar & Bench.

Track this LIVE blog for latest update on coronavirus pandemic

Close

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Justice Chandrachud asked why a national immunisation policy cannot be adopted.

"Will one state get priority access over another in getting the vaccines? Centre says 50 percent will be procured by states for vaccines. How will the vaccine manufacturers ensure equity? Why not follow the National Immunization Program policy...procurement is centralised but distribution be decentralised," Justice DY Chandrachud asked.

For Phase 3 of the COVID-19 vaccination drive, vaccine manufacturers have been permitted to release 50 percent of their supply to states. States can now purchase doses directly from the vaccine makers.

Bharat Biotech has priced Covaxin at Rs 400 per dose for state governments, while Serum Institute of India will sell Covishield at Rs 300. However, the Centre will continue procuring shots at Rs 150 per dose from both companies.
Moneycontrol News
first published: Apr 30, 2021 02:48 pm

stay updated

Get Daily News on your Browser
Sections